Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 5 Jan 2021 |
| Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer | 4 Jan 2021 |
| Genmab A/S has published its Articles of Association | 21 Dec 2020 |
| Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab | 15 Dec 2020 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 15 Dec 2020 |
| Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer | 3 Dec 2020 |